The Franco-German Novasep PharmaZell Group is investing 7.3 million euros in the Mourenx site

This new investment will support the growth of the Mourenx site and support the growing demand for the production of active pharmaceutical ingredients (APIs), particularly high potency drugs (HPAPIs) for the treatment of cancer.

The Novasep PharmaZell Group has announced a €7.3 million investment in its Mourenx site (south-west France) as part of a larger project supported by the France Relance plan to create a pilot multipurpose workplace in one of its create production units.

This investment includes an upgrade of two existing 2000 liter reactors to optimize their versatility and functionality, as well as the addition of a new 1500 liter reactor and a Hastelloy filter drier. The new multi-purpose workshop will be equipped to manufacture batches from 30 to 100 kg for clinical trials, process validation and commercial production of APIs for targeted therapies with a focus on HPAPIs.

“This major project to modernize and expand the Mourenx site shows the determination of our new group to continue the industrial investment strategy that we have successfully pursued for several years,” says Jean Bléhaut, President of the CDMO business unit. “This is a clear signal and practical answer for our pharmaceutical customers, who face increasing challenges to secure supply chains in the area of ​​healthcare products and especially APIs.”

Since the completion of the merger of Novasep and PharmaZell, which took place onth, the new group’s strategy focuses on offering its customers greater competitiveness, secure supply chains and full support throughout the lifecycle of their products. Novasep offers innovators flexible contract development and manufacturing (CDMO) solutions for small molecule APIs and biopharmaceuticals. PharmaZell is a leader in the highly resistant and specialty API market, where it has a diversified portfolio of over 70 APIs and holds leading industry positions in multiple products for the treatment of respiratory, inflammatory and hepatic diseases. Many of the Company’s products require special handling procedures and/or technology. PharmaZell, headquartered in Raubling/Rosenheim (near Munich), operates four state-of-the-art production and R&D locations in Germany, Italy and India with over 900 employees worldwide – now under the Novasep umbrella.

©EuropeanBiotechNews/gkä

Comments are closed.